{
    "root": "2fa5b032-dcc5-09e1-e063-6294a90ad780",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "METHYLPHENIDATE HYDROCHLORIDE",
    "value": "20250305",
    "ingredients": [
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "METHYLPHENIDATE HYDROCHLORIDE",
            "code": "4B3SC438HI",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31836"
        }
    ],
    "indications": {
        "text": "methylphenidate hydrochloride extended-release tablets indicated treatment : attention deficit hyperactivity disorders ( adhd ) pediatric patients 6 years older adults narcolepsy",
        "doid_entities": [
            {
                "text": "adhd (DOID:1094)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1094"
            },
            {
                "text": "narcolepsy (DOID:8986)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8986"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "methylphenidate hydrochloride extended-release tablets ( 2.2 ) : may switch methylphenidate hydrochloride extended-release tablets 8-hour methylphenidate hydrochloride extended-release tablets corresponds titrated 8-hour methylphenidate hydrochloride tablets . must swallowed whole never crushed chewed",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "methylphenidate hydrochloride extended-release tablets , usp available follows : 10 mg : white white , round shaped , uncoated , tablets debossed \u201c fm4 \u201d one side \u201c plain \u201d side . bottles 100 tablets ndc 70010-042-01 bottles 30 tablets ndc 70010-042-03 20 mg : white white , round shaped , uncoated , tablets debossed \u201c fm5 \u201d one side \u201c plain \u201d side . bottles 100 tablets ndc 70010-043-01 bottles 30 tablets ndc 70010-043-03 note : methylphenidate hydrochloride extended-release tablets , usp color-additive free . store 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] . protect moisture . dispense tight , light-resistant container defined usp , child-resistant closure . disposal comply local laws regulations disposal cns stimulants . dispose remaining , unused , expired methylphenidate hydrochloride extended-release tablets , usp medicine takeback program authorized collector registered enforcement . take-back program authorized collector available , mix methylphenidate hydrochloride extended-release tablets , usp undesirable , nontoxic substance make less appealing children pets . place mixture container sealed plastic bag discard methylphenidate hydrochloride extended-release tablets , usp household trash .",
    "adverseReactions": "hypersensitivity methylphenidate components methylphenidate hydrochloride extended-release tablets . hypersensitivity angioedema anaphylactic reported patients treated methylphenidate [ ( 6 ) ] . concomitant treatment monoamine oxidase inhibitors ( maois ) , within 14 days following discontinuation treatment maoi , risk hypertensive crises [ ( 7.1 ) ] .",
    "indications_original": "Methylphenidate hydrochloride extended-release tablets are indicated for the treatment of:\n                  \n                     Attention Deficit Hyperactivity Disorders (ADHD) in pediatric patients 6 years and older and adults\n                     Narcolepsy",
    "contraindications_original": "Methylphenidate hydrochloride extended-release tablets (2.2) : May switch to Methylphenidate hydrochloride extended-release tablets when the 8-hour dosage of Methylphenidate hydrochloride extended-release tablets corresponds to the titrated 8-hour dosage of methylphenidate hydrochloride tablets. Must be swallowed whole and never crushed or chewed",
    "warningsAndPrecautions_original": "Methylphenidate hydrochloride extended-release tablets, USP are available as follows:\n                  10 mg: White to off white, round shaped, uncoated, tablets debossed with \u201cFM4\u201d on one side and \u201cplain\u201d on other side.\n                  Bottles of 100 tablets\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 70010-042-01\n                  Bottles of 30 tablets\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 NDC 70010-042-03\n                  20 mg: White to off white, round shaped, uncoated, tablets debossed with \u201cFM5\u201d on one side and \u201cplain\u201d on other side.\n                  Bottles of 100 tablets\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 70010-043-01\n                  Bottles of 30 tablets\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0NDC 70010-043-03\n                  \n                     NOTE:Methylphenidate hydrochloride extended-release tablets, USP are color-additive free.\n\n \n                  Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted between 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F) [See USP Controlled Room Temperature].\n                  Protect from moisture.\n                  Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure.\n                  \n                     Disposal\n                  \n                  Comply with local laws and regulations on drug disposal of CNS stimulants. Dispose of remaining, unused, or expired Methylphenidate hydrochloride extended-release tablets, USP by a medicine takeback program or by an authorized collector registered with the Drug Enforcement Administration. If no take-back program or authorized collector is available, mix Methylphenidate hydrochloride extended-release tablets, USP with an undesirable, nontoxic substance to make it less appealing to children and pets. Place the mixture in a container such as a sealed plastic bag and discard Methylphenidate hydrochloride extended-release tablets, USP in the household trash.",
    "adverseReactions_original": "Hypersensitivity to methylphenidate or other components of Methylphenidate hydrochloride extended-release tablets. Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with methylphenidate\n  \n   [\n   \n    see Adverse Reactions (6)]\n  \n   .\n \n  \n                     Concomitant treatment with monoamine oxidase inhibitors (MAOIs), or within 14 days following discontinuation of treatment with an MAOI, because of the risk of hypertensive crises\n  \n   [\n   \n    see Drug Interactions (7.1)]\n  \n   .",
    "drug": [
        {
            "name": "METHYLPHENIDATE HYDROCHLORIDE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31836"
        }
    ]
}